DNA Mismatch repair gene expression in recurrent glioblastoma – association to MGMT status and survival

A.M. Stark, A. Doukas, H.H. Hugo, H.M. Mehdorn & J.H. Held-Feindt
Objective: Glioblastoma patients containing a methylated MGMT promotor region show prolonged survival under combined chemo/radiotherapy with temozolomide. There is current evidence that further Mismatch genes, namely MLH1, MSH2 and MSH6, play a pivotal role in the tumor's response to treatment.[for full text, please go to the a.m. URL]